Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 1, 2024
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen
